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Background: CovRS (or CsrRS) is a two-component regulatory system that regulates the production of multiple
virulence factors in Streptococcus pyogenes. covS mutations are often found in isolates recovered from mice that
have been experimentally infected with S. pyogenes and covS mutations enhance bacterial virulence in an invasive
infection mouse model. In addition, covS mutations were detected more frequently in a panel of clinical isolates
from severe invasive streptococcal infections than those from non-severe infections. Thus, covS mutations may be
associated with the onset of severe invasive infections.
Results: Known covS mutations were divided into two groups: (i) frameshift mutations that caused a deletion of
functional regions and (ii) point mutations that caused single (or double) amino acid(s) substitutions. Frameshift
mutations are frequent in mouse-passaged isolates, whereas point mutations are frequent in clinical isolates. The
functions of CovS proteins with a single amino acid substitution in clinical isolates were estimated based on the
streptococcal pyrogenic exotoxin B (SpeB) production and NAD+-glycohydrolase (NADase) activity, which are
known to be regulated by the CovRS system. Point mutations partially, but not completely, impaired the function
of the covS alleles. We also investigated some of the benefits that a partial loss of function in covS alleles with point
mutations might confer on clinical isolates. We found that covS knockout mutants (ΔcovS strains) had an impaired
growth ability in a normal atmosphere in Todd Hewitt broth compared with parental isolates having wild-type or
point-mutated covS.
Conclusions: The loss of CovS proteins in S. pyogenes may confer greater virulence, but bacteria may also lose the
ability to respond to certain external signals recognized by CovS. Therefore, point mutations that retain the function
of CovS and confer hypervirulence may have natural selective advantages.Background
Streptococcus pyogenes is a Gram-positive bacterium that
infects the upper respiratory tract, including the tonsils
and pharynx, which is responsible for post-infection dis-
eases such as rheumatic fever and glomerulonephritis.
S. pyogenes also causes severe invasive diseases including
necrotizing fasciitis [1-5].
S. pyogenes is exclusively a human pathogen and it
possesses many virulence factors that help it to resist
host defense systems. The production of these factors is
thought to be precisely regulated in response to host
environmental conditions such as different infection
sites or host immune system induction levels [6-8]. In* Correspondence: tadaoh@med.nagoya-cu.ac.jp
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reproduction in any medium, provided the orprokaryotes, the regulation of protein production in re-
sponse to fluctuating environmental conditions depends
primarily on two-component regulatory systems, which
consist of a sensor histidine kinase and its cognate res-
ponse regulator [9]. Thirteen two-component regulatory
systems have been described in S. pyogenes, of which the
CovRS system (also known as the CsrRS system) mediates
the control of several virulence factors [10-15]. Specific
isolates from mice infected with S. pyogenes exhibited en-
hanced virulence in mice owing to spontaneous covR or
covS mutations [10,15,16]. In addition, covS mutations
were detected more frequently in a panel of clinical iso-
lates from severe invasive streptococcal infections than in
a panel of clinical isolates from non-streptococcal toxic
shock syndrome [10,16-18]. Thus, Ikebe et al. [18] sug-
gested that covS mutations are closely associated with the
onset of streptococcal toxic shock syndrome.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[10,15,16] and clinical isolates [18] frequently have the
M1 serotype, which is the most widely disseminated glo-
bal serotype [19-21]. Engleberg et al. [15] showed that
most covS mutations were frameshift or nonsense muta-
tions in isolates from mice infected with the M1 strain.
In contrast, all of the spontaneous changes in CovS
detected in clinical M1 isolates [22] resulted from single
amino acid substitutions. Thus, we were interested in
why this difference occurred and we hypothesized that it
was related to the use of animal-passaged isolates in the
first study whereas the latter used clinical isolates. Sev-
eral covS mutations have been reported in other studies
[10,16,18] in addition to the two mentioned previously
[15,22]. In the current study, we first reviewed the differ-
ent types of covS mutations. This suggested that most of
the spontaneous changes in CovS detected in clinical
M1 isolates resulted from single amino acid substitu-
tions, whereas most of the covS mutations detected in
animal-passaged isolates were frameshift mutations. We
also showed that covS mutations comprising single amino
acid substitutions in the clinical isolates partially, but not
completely, impaired the functions of CovS. Finally, we
present some new findings and discuss why covS muta-
tions in clinical isolates are preferentially single amino acid
substitutions, whereas animal-passaged isolates tend to
have frameshift mutations.
Results and discussion
Classification of covS mutations
We investigated all previously reported covS mutations.
The covS mutations were found most frequently in M1
isolates rather than any other serotypes [10,15,18,22, and
our unpublished data]. The covS mutations detected in
M1 strains were divided into two groups: (i) frameshift
or nonsense mutations that caused a deletion in func-
tional regions and (ii) point mutations that caused single
(or double) amino acid(s) substitutions. Of the 34 covS
mutations 25 were detected in isolates from mice in-
fected with the M1 strain were frameshift mutations
(Figure 1A and Additional file 1). In contrast, 16 of 29
covS mutations detected in a panel of clinical isolates
comprised single (or double) amino acid(s) substitutions
(Figure 1B and Additional file 2). Thus, significantly
more frameshift mutations were detected in mouse-
passaged isolates, whereas point mutations were most
frequent in clinical isolates (P < 0.05, Fisher’s exact test).
Assessment of the function of CovS with an amino acid
substitution using two-dimensional gel electrophoresis
(2-DE)
Theoretically, it is possible that a single amino acid sub-
stitution has no effect on CovS function, whereas a large
deletion may affect domains that are critical for itsfunction. However, we previously observed that all four
clinical isolates (strains GT01, K2, AP04, and AP06) with
covS alleles comprising single amino acid substitutions
had lower SpeB production than a clinical isolate having
the wild-type covS when the culture supernatant pro-
teins were analyzed by 2-DE [22]. It is known that covS
positively regulates speB expression [11,13,14], which sug-
gests that mutated covS alleles degrade the function of
CovS [22]. Thus, we were interested in how the functions
of CovS proteins with single amino acid substitutions were
degraded in clinical isolates. Thus, we deleted the covSGT01
allele encoding CovSGT01A206S (a substitution of Ala206
with Ser) from the GT01 isolate. As shown in Figure 2,
the resulting GT01ΔcovS had lower SpeB production than
the parental GT01 isolate, suggesting that CovSGT01A206S
did not completely lose its function.
Evaluation of the function of CovS with an amino acid
substitution based on its NADase activity
S. pyogenes secretes NAD+-glycohydrolase (NADase) as
one of its virulence factors. According to a previous
study [10], mouse-passaged derivatives of a strain car-
rying wild-type CovS exhibited high levels of NADase
activity. A comparison of the entire genome of these
strains also showed that one of the mouse-passaged de-
rivatives had only one genetic change relative to the par-
ental strain carrying the wild-type CovS, which consisted
of a 7-bp insertion in covS. Therefore, we were inter-
ested in the NADase activity of clinical isolates with covS
alleles containing single amino acid substitutions. Table 1
shows that strain 1529ΔcovS had a NADase activity level
of 93.5 U, which was higher than the level of 3.4 U in
parental isolate 1529 with wild-type covS reported in our
previous study [23]. In addition, the activity level of
strain 1529ΔcovS (93.5 U) was higher than the levels of
62.9 U, 57.0 U, 59.8 U, 60.5 U, and 59.4 U found in the
clinical isolates K2, GT01, AP04, AP06, and FI01, re-
spectively, which had point-mutated covS alleles, in this
study and a previous study [23], although isolate CR01
had a level of 114.3 U. The level of GT01ΔcovS was
105.0 U, which was higher than that of parental strain
GT01 that carried CovSGT01A206S. Thus, the NADase
activity levels in isolates with point-mutated covS alleles
were between those of isolates with wild-type covS and
isolates with a complete deletion of covS. This was con-
sistent with previous reports [22,23], where the levels of
NADase in isolates KN01, MDYK, and MUY with wild
type covS were 6.2 U, 3.0 U, and 3.0 U, respectively.
Next, we attempted to complement 1529ΔcovS with
wild-type covS1529 or derivatives, which were cloned into
plasmid vector pLZ12-Km2. Wild-type covS1529 from
isolate 1529 was cloned into pLZ-covS1529 and it re-
duced the NADase activity by 71.5 U from 201.9 U of
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Figure 1 Summary of the analysis presented in Additional file 1: Table S1 and Additional file 2: Table S2. The various point mutations and
frame-shifts indicated were mapped as (p) and (f), respectively, onto the CovS amino acid sequence with putative conserved and functionally-important
domains: TM1 and TM2, transmembrane helixes 1 and 2; HisKA, histidine kinase domain (phosphoacceptor); HATPase, histidine-kinase like ATPase.
See reference [16] and http://www.ncbi.nlm.nih.gov/protein/7259792?report=genbank&log$=protalign&blast_rank=2&RID=HPZN9V5J01R for additional
information about the putative domains. (A) The map was made from the Additional file 1: Table S1. A mutation occurred in a functionally-critical
phosphorylation site (shown in bold in the CovS amino acid sequence) of the protein in isolates 5448-APD1, 2, 3, 4, 5, and 10. (B) The map was
made from the Additional file 2: Table S2. Isolate FI01 had two point mutations, which were mapped as (p*), as well as isolate NIH286. Isolate
NIH44 had two point mutations, which were mapped as (p). The mutation of isolate MGAS2217 was not mapped, because there was not any
information about the site.
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tivity levels in pLZ-covS1529I30L, pLZ-covS1529E428G,
and pLZ-covS1529A206S encoding mutated covS alleles
from isolates K2, AP04 (or AP06), and GT01 were re-
duced by 39.2 U, 17.1 U, and 15.2 U, respectively (Table 1
and Figure 2). Thus, the pLZ-covS1529I30L, the pLZ-
covS1529E428G, and the pLZ-covS1529A206S certainly
retained their abilities to reduce NADase activity, but
the abilities were lower than that of the pLZ-covS1529
with wild-type covS.These results suggest that amino acid substitutions,
such as I30L, E428G, and A206, partially impaired the
function of CovS.
Benefits of partially impaired CovS
According to previous studies [10,16-18], CovS nega-
tively regulates the expression of certain virulent genes;
therefore, a mutation in covS may increase the virulence
in mouse models of infection where it plays a crucial
role in the onset of severe invasive infections. However,
Table 1 NADase activity of S. pyogenes strains
Strain covS covR NADase (Ua) Reference
1529 wt wt 3.4 ± 0.7 [23]
1529ΔcovS ΔcovS wt 93.5 ± 3.5 this study
K2 I30L wt 62.9 ± 4.6 this study
GT01 A206S wt 57.0 ± 3.6 [23]
CR01 M391R wt 114.3 ± 8.7 [23]
AP04 E428G wt 59.8 ± 2.6 this study
AP06 E428G wt 60.5 ± 5.4 this study
FI01 I381T+H437R wt 59.4 ± 4.8 [23]
1529ΔcovR wt ΔcovR 106.7 ± 3.7 this study
GT01ΔcovS ΔcovS wt 105.0 ± 3.2 this study
GT01ΔcovR wt ΔcovR 103.5 ± 6.7 this study
1529ΔcovS (pLZ12-km2) ΔcovS wt 201.9 ± 2.8 this study
1529ΔcovS (pLZ-covS1529) wt wt 130.4 ± 3.4 this study
1529ΔcovS (pLZ-covS1529I381L) I381T wt 176.7 ± 8.9 this study
1529ΔcovS (pLZ-covS1529 H437R) H437R wt 114.5 ± 6.8 this study
1529ΔcovS (pLZ-covS1529I30L) I30L wt 162.7 ± 11.0 this study
1529ΔcovS (pLZ-covS1529E428G) E428G wt 184.8 ± 6.9 this study
1529ΔcovS (pLZ-covS1529A206S) A206S wt 186.7 ± 4.2 this study
1529 (pLZ12-km2) wt wt 2.4 ± 0.16 this study
a NADase activity (Units) ± standard error are indicated. One unit of NADase activity is defined as the amount (μg) of β-NAD cleaved per hour per μl culture
















Figure 2 Two-dimensional gel electrophoresis (2-DE) analysis of exoproteins from S. pyogenes GT01 (A), GT01ΔcovS (B), SF370ΔcovS
(C), and 1529ΔcovS (D). S. pyogenes strains were cultured in 25 ml BHI-Y broth and the proteins in the culture supernatants were subjected to
2-DE analysis using 13 cm Immobiline Drystrip gels (pH 3–10; GE Healthcare Biosciences Co.). Some protein spots identified by LC-MS/MS analysis
are shown. The SpeB spot sizes produced from GT01ΔcovS (B), SF370ΔcovS (C), and 1529ΔcovS (D) were smaller than those from GT01 (A).
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http://www.biomedcentral.com/1756-0500/6/126the loss of CovS function means that S. pyogenes can no
longer adjust to environmental fluctuations. For ex-
ample, environmental Mg2+ is thought to be recognized
by the CovS sensor protein [24]. Therefore, the partial
loss of CovS function may be favorable in nature, but
not under laboratory conditions. This hypothesis led us
to investigate the benefits of covS in S. pyogenes. Previ-
ously, Trevino et al. [25] showed that a covS mutated
strain had a lower growth ability than the parental wild-
type strain in human saliva, but not in Todd Hewitt
broth, which is the standard broth used to culture
S. pyogenes. We were interested in the factor present in
human saliva that is recognized by CovS; therefore,
we repeated this experiment using the isolates 1529,
SF370, and GT01. Bacteria were cultured under essen-
tially the same conditions as those described previously
[25]. However, the CFU (colony forming units)/ml for
overnight THY broth cultures of strains 1529ΔcovS,
SF370ΔcovS, and GT01ΔcovS were lower than or similar
to those of their parental strains; i.e., 1529, SF370, and
GT01, respectively (Figure 3A), whereas the CFU/ml for
overnight THY broth cultures of the isogenic mutant
2221covS::7 bp was four times that of the parental strain
MGAS2221 reported in the previous study [25]. Thus,
we observed two discrepancies: (i) between our results
using isolates 1529, SF370, and GT01 (Figure 3A), and the
previous results based on isolate MGAS2221 [25] and (ii)
between our results with isolate 1529 (or GT01) and
SF370. These discrepancies may be because of strain spec-
ificities. We did not have strain MGAS2221, so we further
investigated the discrepancy between strains SF370 and
GT01 or 1529. First, we analyzed the growth curves of
the covS mutated strains. SF370ΔcovS, 1529ΔcovS, and



















Figure 3 Growth ability of covS mutant S. pyogenes in THY broth. The
(1529ΔcovS, SF370ΔcovS, and GT01ΔcovS), and parental isolates (1529, SF37
performed and they always yielded essentially the same results. The error b
an experimental condition. The CFU/ml for overnight THY broth cultures o
parental strains 1529 and GT01, respectively. The CFU/ml for overnight THY
strain SF370. (B) Natural atmosphere (NA) was used as an experimental conthat of their parental strains; i.e., SF370, 1529, and GT01,
respectively (Figures 4A–C). Thus, there was no disc-
repancy between strains SF370, GT01, and 1529 in terms
of their growth kinetics. In addition, GT01 exhibited de-
layed and advanced growth compared with strain 1529
(or SF370) and strain GT01ΔcovS (Figures 4D and C),
which was consistent with our hypothesis that the A206S
substitutions partially impaired the function of CovS.
The growth abilities of SF370 and its isogenic covS
mutant SF370ΔcovS in THY broth differed from each
other when evaluated on the basis of, but not the CFU/ml
in overnight cultures (Figure 3A), the growth curves
(Figure 4A). This new discrepancy may have occurred be-
cause the overnight culture, but not the growth curve, was
conducted in 5% CO2, which was the condition described
in a previous study [25]. Therefore, we prepared overnight
cultures of wild-type SF370 (SF370wt) and SF370ΔcovS
in natural atmosphere (NA) conditions. As shown in
Figure 3B, the CFU/ml for SF370ΔcovS was lower than
that of its parental strain SF370. Finally, we performed
supplementary and supporting experiments to test the
reliability of this study. covS and covRS cloned into a
plasmid vector complemented the delayed growth of
1529ΔcovS (Figure 5). pLZ-covS1529 and pLZ-covRS1529
increased the CFU/ml for overnight THY broth cultures
of strain 1529ΔcovS (Figure 6). As shown in Figure 7,
1529ΔcovS was hypervirulent in a mouse infection
model compared with the parental strain 1529 (P<0.01),
as shown with other strains and their isogenic ΔcovS
mutants in previous studies [10,16].
Conclusions
On the basis of our results and those from previous
studies we concluded that the loss of covS increases theNAB
CFU/ml after 23 h, THY broth culture of isogenic covS mutant strains
0, and GT01) are shown. At least three independent experiments were
ars indicate the standard errors of the means. (A) 5% CO2 was used as
f strains 1529ΔcovS and GT01ΔcovS were lower than those for their
















































































Figure 4 Growth curves of covS null mutants in THY broth. Three independent experiments produced essentially the same results. Representative
data from three independent experiments are shown. (A-C) SF370ΔcovS, 1529ΔcovS, and GT01ΔcovS all exhibited delayed growth compared with that
of their parental strains SF370, 1529, and GT01, respectively. (D) GT01 exhibited delayed growth compared with strains 1529 and SF370.
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http://www.biomedcentral.com/1756-0500/6/126virulence of S. pyogenes (which is advantageous in vivo).
However, the loss of covS also impaired the growth abil-
ity of this organism in THY broth (which is disadvanta-
geous in vitro). Therefore, the CovRS system may confer
benefits in stages when virulent gene expression is not
required. The expression of many genes is precisely reg-
















Figure 5 Growth curves of streptococcal strains in THY broth.
Bacteria were cultured in THY broth supplemented with kanamycin
(62.5 μg/ml) and the experiments were performed as described in
Figure 4.catabolite repression. Therefore, partial attenuation of
the CovRS system to promote resistance to the host
defense system appears to be a wise choice for survival
in nature.
We did not determine the components recognized by
the CovS sensor proteins in our experimental conditions;
i.e., THY broth, natural atmosphere, or 5% CO2. How-
ever, it was probably not the Mg2+ ion, which was sug-
gested previously [24], because we did not add Mg2+ ion
to THY broth. Therefore, we propose that CovS can
sense other signals in addition to the Mg2+ ion.
Methods
Bacterial strains
Streptococcal strains were isolated as the causative
organisms in patients from Japan [22,23]. S. pyogenes
(GAS) strain SF370, which was the most prevalent data-
base reference isolate (accession number NC_002737),
was provided by J. J. Ferretti [26,27]. Streptococcal
strains were cultured in brain–heart infusion (E-MC62,
EIKEN Chemical Co., Tokyo, Japan) supplemented with
0.3% yeast extract (BD, Sparks, MD, USA), (BHI-Y) broth
or Todd Hewitt broth (BD, Sparks, MD, USA) supplemen-



































Figure 6 Growth of covS mutant S. pyogenes in THY broth with 5% CO2 or NA. These experiments were performed as described in
Figures 3. The error bars indicate the standard errors of the means.
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We constructed S. pyogenes strain 1529ΔcovS as described
previously [28]. Strains GT01ΔcovS and SF370ΔcovS were
constructed using the same strategy [28].
Two-dimensional gel electrophoresis (2-DE)
Each bacterial isolate was cultured in BHI-Y at 37°C
overnight without agitation. Exoproteins from the cul-
ture supernatant were prepared as described previously
[22]. In brief, all sample pellets derived from bacterial
culture supernatant were dissolved in dehydration solu-
tion, which consisted of 7.8 M urea, 2 M thiourea, 2%
CHAPS, 0.6% dithiothreitol, and 0.5% IPG buffer. The
samples were loaded onto 13 cm Immobiline DryStrip gels
(pH 3–10, GE Healthcare Biosciences Co. Piscataway, NJ,






















Figure 7 Survival after skin inoculation with S. pyogenes strain 1529 o
experiments and a total of eight mice for each challenged strain. P < 0.01were carried out according to the manufacture’s in-
struction. Second-dimensional SDS-PAGE separation
was performed as described previously [22]. The expe-
riments were repeated at least 3 times to confirm their
reproducibility.
Production of covR knockout strains
To construct the plasmid for the covR knockout mutant,
the 50 end of covR (fragment 1) was amplified using the
oligonucleotide primer covR-n6 (50-GGCTAGCCTTT
AGAGAATATGGTTACT-30) with an NheI restriction
site and primer covR-c2 (50-TCCCCCGGGCTTTGTCA
TTTATACCAACC-30) with an SmaI restriction site, while
the 30 end of covR (fragment 2) was amplified using
the primer covR-n7 (50-TCCCCCGGGGAGAAATAAGTC




r isogenic mutant 1529ΔcovS. Data were from two independent
for comparison between strains.
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C-30) with an SpeI restriction site. Fragment 2 was di-
gested with SmaI and SpeI before its insertion into
multicloning site 2 in the plasmid pFW12 [29]. The
resulting plasmid was digested using NheI and SmaI, and
the spc1 DNA fragment containing aad9 (promoterless
spectinomycin resistance gene), which was obtained from
a SmaI-digested fragment of pSL60-1 [29], and the NheI-
SmaI-digested fragment 1 were inserted. This plasmid,
covR::aad9/pFW12, was a suicide vector for S. pyogenes.
To prepare competent cells, strains 1529 and GT01 were
harvested in the early to mid-log phase (OD660, 0.4) and
washed twice with 0.5 M sucrose buffer. The suicide vec-
tor construct, covR::aad9/pFW12, was transformed into
strains 1529 and GT01 via electroporation. The conditions
for electroporation were 1.25 kV/mm, 25-μF capacitance,
and 200-Ω resistance, and it was performed using a
GenePulser II instrument (Bio-Rad, Hercules, CA). After
incubation at 37°C for 3 h, competent cells were spread
onto BHI agar plates containing 0.3% yeast extract and
spectinomycin (final concentration, 100 μg/ml). Selected
colonies were cultured from the plates. The cultured bac-
teria were washed once with saline, resuspended in
10 mM Tris-1 mM EDTA, and boiled for 10 min. Gen-
omic DNA was obtained from the supernatant of the
boiled bacteria. The double-crossover replacement was
analyzed by PCR using genomic DNA. Successful double-
crossover replacement was further confirmed by DNA
sequencing.
Quantification of the NADase activity in the bacterial
supernatant
NADase activity was determined using the method of
Stevens et al. [30] as described previously [31].
Plasmids
pLZ-covS1529, pLZ-covS1529I30L, and pLZ-covS1529E428G
were constructed as described previously [22]. To con-
struct pLZ-covS1529A206S, the DNA fragment was
amplified using the oligonucleotide primers covR-n2
(50-CTTTAGAGAATATGGTTACT-30), covS-c2 (50-GT
AATTACATTTTGGACAAC-30), and GT01 genomic
DNA as templates with TaKaRa Ex Taq DNA poly-
merase (Takara, Ohtsu, Japan). The fragment consisted of
covRGT01, covSGT01, and their 5
0-noncoding region, which
possibly contained the promoter region. This fragment
was cloned into the pGEM-T vector (Promega, Madison,
WI, USA). The resultant plasmid was digested with EcoRI
and ligated into the same site in the pLZ12-Km2 plasmid
[32] (pLZ-covRSGT01). To construct a plasmid containing
only the covSGT01 region, inverse PCR was conducted
using two primers, covR-c2Sma (50-TCCCCCGGGC
TTTGTCATTTATACCAACC-30) and covR-n7Sma (50-
TCCCCCGGGGAGAAATAAGTCATATGGAA-30), withpLZ-covRSGT01 plasmid DNA as template and Prime-
STAR HS DNA polymerase (Takara) to eliminate the covR
region. This blunt-ended PCR product was treated with
T4 polynucleotide kinase (Takara) and self-ligated. The re-
sultant plasmid was pLZ-covS1529A206S. pLZ-covRS1529
encoding the covRS1529 operon of isolate 1529 was
constructed as described previously [22]. All of the covRS
DNA sequences were confirmed by sequencing.Mouse model of invasive skin tissue infection
All animal studies conducted comply with federal and
institutional (the Committee on the Ethics of Animal
Experiments of the Nagoya City University) guidelines.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Nagoya City Uni-
versity (Permit Number: H23M-07). All efforts were
made to minimize suffering.
The ability of S. pyogenes to cause local skin lesions
and necrosis in mice after skin inoculation was assessed
using a similar procedure to that described previously
[23,33]. Three-week-old female ICR mice (10–12 g) were
anesthetized with sevoflurane and the skin of the left
flank was laid bare by separating the hair with an alcohol
swab, unless indicated otherwise. Bacteria (0.2 ml; 2 ×
107 CFU/mouse) grown in BHI-Y were injected immedi-
ately beneath the surface of the skin using a 27-gauge
needle so a superficial bleb appeared below the skin sur-
face. The number of CFU injected was verified in each
experiment by plating bacteria on BHI-Y or sheep blood
agar plates and counting the CFU.Statistical analysis
The survival times were assessed using a log-rank com-
parison. The R program was used for the statistical ana-
lysis http://bioinf.wehi.edu.au/software/russell/logrank/
webcite. P ≤ 0.05 was considered significant.Availability of supporting data
There are two supplementary tables.Additional files
Additional file 1: Table S1. csrS mutations from mouse-passaged
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